Established since 2006, we operate solely within the Pharma, Biotech and Medical Device industries. We work in partnership with a wide range of clients, from blue-chip manufacturers to specialist boutique consultancies, supporting them all in finding talented individuals for their permanent and contract vacancies. If you are looking to attract new people to your team or you’re a candidate looking for a new opportunity, then we’d love to hear from you.
Our expertise runs right through the product lifecycle, from clinical research to commercialisation, and our Consultant teams are split out by sector, meaning that they are very specialised in what they do with strong networks and excellent knowledge of their specific markets.
To find out more about our story and our areas of expertise, please click through to the ‘Our Story’ section of the website. And if you can’t find what you’re looking for or have any questions whatsoever, please don’t hesitate to call us on +44 (0)1625 541 030 and the team will be very happy to help.
This year, we've partnered with the fantastic Children's Farm Trust as our corporate charity. Find out more about how the money we raise can help them - and why we're walking to New Zealand and back to do so - here!
No CV? No problem! Use “Apply with Linked In” when you apply for jobs and it magically sends us your profile.
We can’t find you a fab new job if you don’t... And we’d never do anything naughty with your info.
By Nicola Simpson, Med Comms Associate Consultant
Glassdoor - one of the world's largest job and recruiting websites - has 32 million unique monthly users. That's 32 million people who could be looking at authentic reviews left online about your company. So if the candidates you're looking to attract are highly engaged and well-researched, they'll obviously want to take advantage of a website which gives them insider knowledge on the company they are interested in.
Glassdoor can provide job seekers with information on salaries, benefits, company culture and more. This can provide potential employees with invaluable advice they wouldn't have gathered from a job advert alone - so why do so many companies ignore the reviews (both positive and negative) left on sites such as Glassdoor, especially when these reviews could be so influential in the decision making process of potential new employees?
Below we'll take a look at several ways in which companies can ensure they're portrayed on review websites in the best possible light.
Every company will have experienced disgruntled employees in the past. And just like with sites such as TripAdvisor, people are more likely to leave a review if they've had a bad experience as opposed to a good one. It should be expected there will be the odd negative review left about the company you're looking to interview at - what's important is that the company has responded to all these negative comments in a timely and professional manner.
To offset any negative comments it'd be worthwhile encouraging current employees to leave comments too. They should feel free to write what they want (it's an anonymous forum after all) and ask them to comment in dribs and drabs over several weeks and months. This will ensure your Glassdoor profile looks more credible, instead of a sudden rush of reviews all left within a couple of days.
There are bound to be plenty of team members with really great things to say about the company, who hadn't even thought about writing an online review - so encourage them to do so! It's also a great chance for current employees to get their voices heard.
Why do companies ignore their bad reviews? If these aren't a regular occurrence - and the company knows this isn't how the majority of their staff feels - they might not see the need to respond. Yet future employees might view these comments as the truth. Or that any issues they have with the company may not be listened to.
It is always worthwhile regularly checking company reviews - you should welcome all feedback, address specific negative experiences and amplify your positive reviews. This will show you are a transparent company who values feedback. It'll also hopefully show potential future employees that the negatives reviews were either one off experiences or factors you are working to improve.
Glassdoor, and other company review sites, can be of use in helping your company uncover issues you were previously unaware of. If a few reviews are giving the same feedback, for instance asking for more regular appraisals or more flexible working options, you can use this feedback to implement positive changes. Viewing these reviews as constructive criticism will show staff you value their feedback, and these changes are likely to increase both your staff retention and your employee's job satisfaction.
We can't state enough how important company review sites are both to attracting new talent and retaining that which you already have. By implementing a few of these tips, you'll be able to successfully improve your company's online presence, whilst showing you value and take on board both positive and negative comments about how you run things.
For a more in-depth look at how best to utilise Glassdoor for your recruitment needs check out this fab article here.
By Chris Costello, Market Access Consultant
Graduating this summer with a Life Sciences degree?
Fancy working in 'Healthcare' or 'Pharma' but don't want to work in a Lab?
In line with the time of year and the job hunt that most graduates now face, I am often surprised / astounded at how unaware candidates are of the options that exist in today's market for them. A BSc Lifesciences Degree can open a lot of doors and lead to a very fulfilling (and often lucrative) career, but you must start somewhere and that's where I feel grads could do with some extra help.
Every day myself and my colleagues field calls from bright, articulate and well qualified graduates who are looking for that first step into Pharma but, when asked what area of Pharma they are interested in, the answer of "I'm not sure, just Pharma" is an all too common response.
As a comparison and whilst (obviously) not as glamorous and as famous as the footballing world, this is the equivalent to ringing Manchester United's main reception and asking for "a job in football". We all know there are so many roles that exist in football - such as scouting, commercial, legal, support sales, operations, finance, physiotherapy, strength & conditioning, administrative etc - but, because all of these areas are so well defined most people will have some sort of inclination towards one or two areas and, naturally, pursue that particular path.
Whilst Pharma isn't as clearly defined as the roles within a football club, and switching paths is by all means possible, the focus (similar to the football analogy) should always be on what you enjoy the most and what you want to do in the future! There are so many different career paths in the Pharma / Lifesciences industry that, whatever your passions or inclinations, I am very confident that there will be a route for you.
Here at Carrot, we'd recommend thinking about the following to help you decide which career path within pharma to take:
For further information to help you with this big decision, both Prospects and the ABPI have written fantastic articles on which sectors within pharma you Life Sciences degree could help you transfer in to.
Many of the big pharma companies run their own graduate schemes (as opposed to going through a recruiter) but to give you an idea of the type of roles out there within the industry you can take a look at our jobs page here.
Representatives from the Royal College of Radiologists, the British Nuclear Medicine Society and the UK Radiopharmacy Group have written a letter to Prime Minister Boris Johnson to inform them on their concerns over the nation's ability to deliver cancer treatments to patients if the UK crashes out of the EU without a deal. (Source: pharmafile.com)
Progress has been made with the detection of Alzheimer's disease. Researchers claim they can accurately identify people on track to develop the disease, before symptoms appear. US scientists were able to use levels of a protein in the blood to help predict its build-up in the brain. (Source: bbc.co.uk)
The chair of the Royal College of General Practitioners, Helen Stokes-Lampard, has written a letter to new prime minister Boris Johnson outlining the College's concerns around protection of the NHS, and no-deal Brexit among other things. (Source: pharmatimes.com)
AstraZeneca (AZ) has announced that in its first half of 2019 product sales grew 12% to $11,183m, including an acceleration in second-quarter product sales to $5,718m. (Source: pharmatimes.com)
Pfizer's off-patent division, Upjohn is set to merge with the large but struggling generic-drug firm, Mylan. The all-stock transaction, announced on July 29th, would create the world's largest generics firm by revenue, with an enterprise value of $50bn. (Source: economist.com)
Neuralink, a secretive "brain-machine interface" start-up owned by Elon Musk, revealed that it has been working on creating a wireless implantable device that can, theoretically, read your mind. (Source: theguardian.com)
The health minister for the Democratic Republic of Congo (DRC) has previously suggested that a Johnson & Johnson vaccine could have clinical trials in his country to help battle the Ebola outbreak however, this has now been rejected. (Source: europeanpharmaceuticalreview.com)
The Home Office has released its annual statistics on animals used in research in Great Britain. It shows 3.52 million procedures were carried out in 2018, a 7% decrease on the 2017 numbers. (Source: pharmafield.co.uk)
US researched are claiming that by listening to the "world's most relaxing song" that patients' nerves can be calmed just as effectively as when using a sedative. (Source: bbc.co.uk)
GlaxoSmithKline has announced positive headline results from its Phase III PRIMA study of Zejula (niraparib) for patients with ovarian cancer in the first line maintenance setting. (Source: pharmatimes.com)
By guest blogger Preeti Parikh - Head of Business Development at RAS LifeScience Solutions, a boutique pharma/life sciences consulting firm.
It's been almost 3 years since the British public voted 52-48% to leave the EU on 23rd June 2016.12 Given the lack of clarity and ensuing uncertainty pharmaceutical companies, both in the UK and across Europe, have been planning for a worst-case scenario - leaving the EU with no-deal. In this blog, we'll take a look at the most important (subjectively assessed) implications of a no-deal Brexit scenario for pharmaceutical industry.
Before I discuss the potential consequences of a no-deal Brexit, here are some metrics that reflect the importance of the bond between the EU and the UK´s pharmaceutical economy8:
According to ABPI, every month 45 million packets of medicines move from the UK to Europe, and 37 million packs go in the opposite direction. Clearly, exiting the EU will have a significant impact on both markets. While multiple Brexit scenarios have been predicted, I will highlight the impact of a "no-Brexit" scenario on the pharmaceutical industry.
First, a quick recap
On March 29, 2017, the UK notified the European Council that it will withdraw from the EU by March 29th, 2019. However, unable to do so for several reasons, the UK requested and received an extension from the Council (in April 2019) for a new withdrawal date of October 31st, 2019.1,2
A "no-deal" Brexit scenario essentially means the UK would leave the EU without specific agreements in place about what UK-EU industrial/business relationships would look like going forward. Below are the key implications (as I see it) of a no-deal Brexit.
Stockpiling on a rolling basis
In August 2018, pharmaceutical companies were asked to develop six-week stockpiles for some drugs (~7000 essential medicines) to ensure a continuous supply in the event of a no-deal Brexit. However, on April 26th 2019, the Department of Health and Social Care asked these companies to keep their six-week stockpiles of medicines "in place but on hold" until further notice.3
Stockpiling on a rolling basis increases the financial burden on the manufacturers and creates costly inefficiencies, especially for medicines with short shelf-lives. Warehousing medical stock also creates an additional cost burden, with the uncertainty of the situation hindering the companies´ ability to plan ahead.
In the short term, many UK companies are beginning to move their facilities outside the country. GSK, for example, are building new laboraties in Europe so they can also test their products outside of the UK to ensure they can still be sold in the EU. Similarly, AstraZeneca have taken the position of halting all spends on stockpiling and risk the wrath of regulators in case of shortage due to a no-deal Brexit.6,7,13
Access to Public and Private Capital
A no-deal Brexit would reduce the UK's funding from the EU's Horizon 2020 programme (a £70B pot aimed at cutting-edge science) by ~50%. The UK´s access to EU funding beyond Horizon 2020 is still uncertain, meaning the UK could lose vital access to EU public funds.4,5,10
Access to private capital will also be adversely affected in the case of a no-deal Brexit: non-UK based venture capital and private equity funds will tighten their criteria of funding UK based biopharmaceutical companies, since the entry barriers to EU markets will increase.4
Costly marketing approvals
In case of a no-deal Brexit, the UK's MHRA will take over the regulatory functions currently performed by the EMA, including managing regulatory applications for medicines.9
This implies that UK companies will have to partner with and/or set up legal base(s) within EU countries to develop and commercialize their products for the EU market.11 The same holds true for EU companies as they try to access the UK market. These stipulations have the potential to hurt the bottom line of pharma companies with cross border ambitions.
The pharmaceutical industry (like all others) is currently in a 'wait-and-watch' mode as the UK tries to make an exit plan from the EU. The prospect of clarity seems distant, as trade negotiations are expected to go on for several years - impying decisions won't be made before the EU withdrawal deadline and therefore leaving the UK with a no-deal Brexit.
In the meantime, the increased cost of business and restricted access to capital is likely to adversely impact the UK´s pharma industry.
So, what does the future hold for Britain's pharmaceutical industry? We will have to wait and see... and prepare for Brexit....deal or no-deal!
EU: European Union
EC: European Commission
MHRA: Medicines and Healthcare products Regulatory Agency
EMA: European Medicines Agency
ABPI: Association of the British Pharmaceutical Industry
MAH: Marketing Authorization Holders
EEA: European Economic Area
API: Active Pharmaceutical Ingredient
This article was first published on the RAS website on 12th July 2019.